 | |
| Clinical data | |
|---|---|
| Trade names | Ravicti |
| AHFS/Drugs.com | Micromedex Detailed Consumer Information |
| License data | |
| Routes of administration | By mouth |
| ATC code | |
| Legal status | |
| Legal status | |
| Identifiers | |
| |
| CAS Number | |
| PubChemCID | |
| DrugBank | |
| ChemSpider | |
| UNII | |
| ChEMBL | |
| CompTox Dashboard(EPA) | |
| ECHA InfoCard | 100.228.552 |
| Chemical and physical data | |
| Formula | C33H38O6 |
| Molar mass | 530.661 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
Glycerol phenylbutyrate, sold under the brand name Ravicti, is a nitrogen-binding agentmedication used in the treatment of certain inbornurea cycle disorders. The medication works by preventing the harmful buildup ofammonia in the body.[4] It is an FDA-approved prescription drug in the US.[5] It was developed byHyperion Therapeutics based on the existing medicationsodium phenylbutyrate, and received approval in February 2013.[6]
Glycerol phenylbutyrate isindicated for chronic management of people with urea cycle disorders who cannot be managed by dietary protein restriction and/or amino acid supplementation alone.[2]
Hyperion has been criticized for setting a high price for the drug. The price was set at US$250,000–290,000. In 2014, the drug generated $30.8 million in net sales, far behind the older and less expensive Buphenyl ($113.6 million in sales).[7]
